The global Minimal Residual Disease Market was valued at USD 2.53 billion in 2024 and is expected to reach USD 9.16 billion by 2034, growing at a CAGR of 13.7%. Increasing prevalence of hematologic cancers, rising demand for precision oncology, and the integration of advanced molecular diagnostic techniques are fueling market growth. Minimal residual...